TB-500

The TB-500 / Thymosin β4 evidence base rests heavily on two foundational rodent Nature mechanism papers and a small set of human clinical signals — almost all of them in indications other than the muscle-and-tendon repair claims that drive most off-label adoption. Bock-Marquette 2004 and Smart 2007 together established the cardiac-repair mechanism (ILK/Akt-driven cardiomyocyte survival; epicardial vascular-progenitor mobilization), and the entire RegeneRx clinical-development arc was built on top of them. The translation has been partial. The Phase 2 acute myocardial infarction program (RGN-352) did not produce a successful Phase 3 readout, and the most ambitious early framing — that Thymosin β4 might reprogram adult epicardium into cardiomyocytes — was substantially narrowed by subsequent lineage-tracing work (Zhou et al., Circulation Research 2013) to vascular-progenitor mobilization rather than full cardiomyocyte regeneration.

The human safety and ophthalmic-efficacy signals are the only clinical evidence base of any substance. Ruff et al. 2010 is the gating Phase 1 paper — 40 healthy volunteers, intravenous Thymosin β4 at 42, 140, 420, or 1260 mg with subsequent daily dosing for 14 days, dose-proportional pharmacokinetics, no dose-limiting toxicities and no serious adverse events across the full dose range. That is the only published human IV-dosing safety dataset for the full-length molecule, and it does not transfer cleanly to either the 17-amino-acid fragment sold as TB-500 or to the chronic subcutaneous dosing typical in the off-label market. On the efficacy side, two 2015 ophthalmic Phase 2 trials of 0.1% Thymosin β4 ophthalmic solution (RGN-259) are the load-bearing human readouts. Sosne et al. 2015 (Cornea) reported a 35.1% reduction in ocular discomfort and a 59.1% reduction in corneal fluorescein staining at day 56 in nine patients with severe dry eye. The larger 72-patient companion trial, Sosne and Ousler 2015 (Clinical Ophthalmology), did not meet its prespecified primary endpoints, although secondary controlled-adverse-environment analyses showed a 27% discomfort reduction during exposure and significant improvements on two corneal-staining measures. The subsequent Phase 3 dry-eye program (ARISE-1, ARISE-2, ARISE-3) has not produced a successful pivotal readout, which is the load-bearing fact for anyone interpreting ophthalmic TB-500 claims.

The sports and anti-doping context is its own conversation. TB-500 is on the World Anti-Doping Agency's Prohibited List year-round, in the S2 peptide-hormones-and-growth-factors class. Mendias and Awan 2026, the 2026 Sports Medicine narrative review from the Performance Medicine Institute, places TB-500 explicitly within the unapproved gray-market peptide cohort alongside BPC-157, CJC-1295, ipamorelin, MOTS-C, GHK-Cu, and SS-31, and constructs an evidence-based framework for clinician-patient discussion. The review notes — and the corpus agrees — that mechanism-plus-rodent-data plus practitioner observation does not substitute for adequately powered human controlled trials, and that the placebo effect amplified by social media is a real mediator of perceived efficacy in this category. The biohacker, equestrian, and soft-tissue-injury case for TB-500 rests on actin-binding mechanism, decades of preclinical migration / angiogenesis / inflammation modulation work in rodents and equines, and accumulated practitioner anecdote — not on randomized controlled musculoskeletal-repair trial data, of which there is essentially none for the fragment sold as TB-500.

The honest framing: Thymosin β4 is mechanistically one of the most interesting healing-class peptides in the literature, with a real Phase 1 safety dataset, two Phase 2 ophthalmic signals, and a Phase 3 program in neurotrophic keratopathy and dry eye that has not delivered. The translation from that body of work to systemic subcutaneous dosing of the 17-amino-acid TB-500 fragment for tendon, muscle, and soft-tissue repair is an extrapolation, not a demonstration. The soft-tissue healing decision guide walks the BPC-157-versus-TB-500 stack reasoning at decision level, and the healing and angiogenesis dossier places both peptides in the broader pro-angiogenic risk frame that anyone with a personal or family cancer history needs to weigh before use.